Click here to get full coverage on SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Yahoo Finance

SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy  Yahoo Finance

SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Yahoo Finance

Click here to get full coverage on Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - simplywall.st

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky  simplywall.st

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - simplywall.st

Click here to get full coverage on Scynexis: Q4 Earnings Snapshot - KING5.com

Scynexis: Q4 Earnings Snapshot  KING5.com

Scynexis: Q4 Earnings Snapshot - KING5.com

Click here to get full coverage on SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M - Stock Titan

SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M  Stock Titan

SCYNEXIS (NASDAQ: SCYX) transfers BREXAFEMME NDA to GSK, up to $145.5M - Stock Titan

Click here to get full coverage on Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC - GuruFocus

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC  GuruFocus

Final SCYX Investor Deadline: Bronstein, Gewirtz & Grossman LLC - GuruFocus

Click here to get full coverage on SCYNEXIS Reports Q4 2025 Milestones and Financial Results, Including $24.8 Million Payment from GSK and Advancements in SCY-247 Development - Quiver Quantitative

SCYNEXIS Reports Q4 2025 Milestones and Financial Results, Including $24.8 Million Payment from GSK and Advancements in SCY-247 Development  Quiver Quantitative

SCYNEXIS Reports Q4 2025 Milestones and Financial Results, Including $24.8 Million Payment from GSK and Advancements in SCY-247 Development - Quiver Quantitative

Click here to get full coverage on Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation - Yahoo Finance

Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation  Yahoo Finance

Here's Why We're A Bit Worried About SCYNEXIS' (NASDAQ:SCYX) Cash Burn Situation - Yahoo Finance

Click here to get full coverage on Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com - Investing.com South Africa

Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com  Investing.com South Africa

Brookline Capital cuts SCYNEXIS stock price target on valuation By Investing.com - Investing.com South Africa

Click here to get full coverage on New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - Stock Titan

New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi  Stock Titan

New antifungal SCY-247 shows potent activity against deadly drug-resistant fungi - Stock Titan

Click here to get full coverage on SCYX Achieves Key Milestones and Exceeds Q3 Revenue Expectations - GuruFocus

SCYX Achieves Key Milestones and Exceeds Q3 Revenue Expectations  GuruFocus

SCYX Achieves Key Milestones and Exceeds Q3 Revenue Expectations - GuruFocus

Click here to get full coverage on SCYNEXIS receives $22 million from GSK as MARIO study ends - Investing.com

SCYNEXIS receives $22 million from GSK as MARIO study ends  Investing.com

SCYNEXIS receives $22 million from GSK as MARIO study ends - Investing.com

Click here to get full coverage on SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties - Quiver Quantitative

SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties  Quiver Quantitative

SCYNEXIS Completes BREXAFEMME NDA Transfer to GSK, Positioning for Future Milestones and Royalties - Quiver Quantitative

Click here to get full coverage on SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock - Stock Titan

SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock  Stock Titan

SCYNEXIS Antifungal Drug Cleared by FDA, but GSK Partnership Hits Major Roadblock - Stock Titan

Click here to get full coverage on Scynexis Inc earnings beat by $0.12, revenue topped estimates - Investing.com

Scynexis Inc earnings beat by $0.12, revenue topped estimates  Investing.com

Scynexis Inc earnings beat by $0.12, revenue topped estimates - Investing.com

Click here to get full coverage on SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations  Yahoo Finance

SCYNEXIS Second Quarter 2025 Earnings: Beats Expectations - Yahoo Finance

Click here to get full coverage on SCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study Termination - Quiver Quantitative

SCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study Termination  Quiver Quantitative

SCYNEXIS to Receive $22 Million Payment from GSK Following MARIO Study Termination - Quiver Quantitative

Click here to get full coverage on Scynexis receives 180-day extension from Nasdaq to meet listing requirements - Investing.com

Scynexis receives 180-day extension from Nasdaq to meet listing requirements  Investing.com

Scynexis receives 180-day extension from Nasdaq to meet listing requirements - Investing.com

Click here to get full coverage on SCYNEXIS Secures $24.8 Million Payment from GSK and Advances SCY-247 Development Plans Amid Phase 3 Study Termination | SCYX Stock News - Quiver Quantitative

SCYNEXIS Secures $24.8 Million Payment from GSK and Advances SCY-247 Development Plans Amid Phase 3 Study Termination | SCYX Stock News  Quiver Quantitative

SCYNEXIS Secures $24.8 Million Payment from GSK and Advances SCY-247 Development Plans Amid Phase 3 Study Termination | SCYX Stock News - Quiver Quantitative

Click here to get full coverage on SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks

SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price  TipRanks

SCYNEXIS Faces Nasdaq Delisting Notice for Stock Price - TipRanks

Click here to get full coverage on 12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session  Benzinga

12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga

Click here to get full coverage on SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - Bitget

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247  Bitget

SCYNEXIS Announces First Participants Dosed in a Phase 1 Single Ascending Dose and Multiple Ascending Dose Trial of Intravenous SCY-247 - Bitget

Click here to get full coverage on Aug PostEarnings: Does SCYX meet Warren Buffetts criteria - Earnings Overview Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Aug PostEarnings: Does SCYX meet Warren Buffetts criteria - Earnings Overview Summary & Free Real-Time Volume Trigger Notifications  baoquankhu1.vn

Aug PostEarnings: Does SCYX meet Warren Buffetts criteria - Earnings Overview Summary & Free Real-Time Volume Trigger Notifications - baoquankhu1.vn

Click here to get full coverage on Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years  Yahoo Finance

Investors in SCYNEXIS (NASDAQ:SCYX) have unfortunately lost 89% over the last five years - Yahoo Finance

Click here to get full coverage on Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX) - Seeking Alpha

Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX)  Seeking Alpha

Scynexis: Update Following Restructuring Of GSK Deal (NASDAQ:SCYX) - Seeking Alpha

Click here to get full coverage on SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - Stock Titan

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit  Stock Titan

SCYNEXIS to Participate in the 2024 Maxim Healthcare Virtual Summit - Stock Titan

Click here to get full coverage on Class Action Lawsuit Filed Against SCYNEXIS, Inc. (SCYX) on - GlobeNewswire

Class Action Lawsuit Filed Against SCYNEXIS, Inc. (SCYX) on  GlobeNewswire

Class Action Lawsuit Filed Against SCYNEXIS, Inc. (SCYX) on - GlobeNewswire

Click here to get full coverage on Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade) - Seeking Alpha

Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade)  Seeking Alpha

Scynexis: From Fungal To Bungle, The Brexafemme Recall And A Slippery Slope (Rating Downgrade) - Seeking Alpha

Click here to get full coverage on Scynexis: Stock Has Been Punished Enough: GSK Partnership, Revenue Potential Warrant A Buy - Seeking Alpha

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Revenue Potential Warrant A Buy  Seeking Alpha

Scynexis: Stock Has Been Punished Enough: GSK Partnership, Revenue Potential Warrant A Buy - Seeking Alpha

Click here to get full coverage on Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX) - simplywall.st

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX)  simplywall.st

Market Sentiment Around Loss-Making SCYNEXIS, Inc. (NASDAQ:SCYX) - simplywall.st

Click here to get full coverage on Anti-Fungus Stock Surges After Warnings Over Drug-Resistant Strain - Bloomberg.com

Anti-Fungus Stock Surges After Warnings Over Drug-Resistant Strain  Bloomberg.com

Anti-Fungus Stock Surges After Warnings Over Drug-Resistant Strain - Bloomberg.com

Click here to get full coverage on Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus

Avidity Partners Management LP's Strategic Acquisition in SCYNEX  GuruFocus

Avidity Partners Management LP's Strategic Acquisition in SCYNEX - GuruFocus

Click here to get full coverage on The SCYNEXIS (NASDAQ:SCYX) Share Price Is Down 90% So Some Shareholders Are Rather Upset - simplywall.st

The SCYNEXIS (NASDAQ:SCYX) Share Price Is Down 90% So Some Shareholders Are Rather Upset  simplywall.st

The SCYNEXIS (NASDAQ:SCYX) Share Price Is Down 90% So Some Shareholders Are Rather Upset - simplywall.st

Click here to get full coverage on Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock - Yahoo Finance

Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock  Yahoo Finance

Analyst Sees Multiple Chances With Over 300% Upside Potential For This Fungal Infections Stock - Yahoo Finance

Click here to get full coverage on Scynexis CEO acquires $27,400 in company stock - Investing.com Nigeria

Scynexis CEO acquires $27,400 in company stock  Investing.com Nigeria

Scynexis CEO acquires $27,400 in company stock - Investing.com Nigeria

Click here to get full coverage on SCYNEXIS (SCYX) Stock Price, News & Analysis - MarketBeat

SCYNEXIS (SCYX) Stock Price, News & Analysis  MarketBeat

SCYNEXIS (SCYX) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on 'The Big Short' investor Michael Burry revealed a stake in a tiny biotech company last week that has since soared 42% - markets.businessinsider.com

'The Big Short' investor Michael Burry revealed a stake in a tiny biotech company last week that has since soared 42%  markets.businessinsider.com

'The Big Short' investor Michael Burry revealed a stake in a tiny biotech company last week that has since soared 42% - markets.businessinsider.com

Click here to get full coverage on SCYNEXIS (SCYX) Earnings Date and Reports 2026 - MarketBeat

SCYNEXIS (SCYX) Earnings Date and Reports 2026  MarketBeat

SCYNEXIS (SCYX) Earnings Date and Reports 2026 - MarketBeat

Click here to get full coverage on SCYX News Today | Why did SCYNEXIS stock go down today? - MarketBeat

SCYX News Today | Why did SCYNEXIS stock go down today?  MarketBeat

SCYX News Today | Why did SCYNEXIS stock go down today? - MarketBeat

Click here to get full coverage on SCYNEXIS Appoints Christine Coyne as Chief Commercial Officer - citybiz

SCYNEXIS Appoints Christine Coyne as Chief Commercial Officer  citybiz

SCYNEXIS Appoints Christine Coyne as Chief Commercial Officer - citybiz

Click here to get full coverage on SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday - Defense World

SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday  Defense World

SCYNEXIS (SCYX) Projected to Post Quarterly Earnings on Wednesday - Defense World

Click here to get full coverage on SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above 50 Day Moving Average – What’s Next? - Defense World

SCYNEXIS (NASDAQ:SCYX) Stock Price Passes Above 50 Day Moving Average – What’s Next?  Defense World

SCYX

Price Chart

Key Statistics

Technicals

About SCYX

Latest News

SCYNEXIS, Inc. (SCYX) Announces First Participants Dosed in Phase 1 Trial of SCY-247 Antifungal Therapy - Yahoo Finance

Companies Like SCYNEXIS (NASDAQ:SCYX) Could Be Quite Risky - simplywall.st

Scynexis: Q4 Earnings Snapshot - KING5.com

Advanced Charts

Top Gainers

Top Losers